Drug Trial Radar · NCT03313778
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
161
Actual
Start
Aug 14, 2017
Primary completion
Nov 21, 2027
Study completion Nov 21, 2027
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Conditions
- Solid Tumors
Interventions
mRNA-4157Biological
IM injection
PembrolizumabBiological
Intravenous infusion
SoC TreatmentBiological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Part A and A2: Baseline through 100 days after last mRNA-4157 dose; Parts B, C, D, E1, E2, and E3: Baseline through 90 days after last pembrolizumab dose
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Angeles Clinic and Research Institute
Los Angeles, California
The George Washington Cancer Center
Washington D.C., District of Columbia
Orlando Health Cancer Institute
Orlando, Florida
Florida Cancer Specialists
Sarasota, Florida
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
NYU Langone Medical Center
New York, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
UT Southwest Medical Center
Dallas, Texas
St Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
Westmead Hospital-Cnr Hawkesbury and Darcy Road
Westmead, New South Wales, Australia
One Clinical Research Perth
Nedlands, Western Australia, Australia
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Tokyo, Japan
National Cancer Center East
Kashiwa-Shi, Chiba, Japan
Kindai University Hospital
Osakasayama-Shi, Ôsaka, Japan
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan
Imperial College Healthcare NHS Trust Hammersmith Hospital
London, United Kingdom
Ninewells Hospital - PPDS
Dundee, Scotland, United Kingdom
Royal Mardsen Sutton
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.